A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit

Immunology and Cell Biology

Volumn 76, Issue 3, 1998, Pages 280-287

  Ågren, Lena ^a   Löwenadler, Björn ^b   Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

ADP ribosylation; Cholera toxin; Costimulation; Mucosal; Targeted adjuvants

Indexed keywords

CHOLERA TOXIN; IMMUNOLOGICAL ADJUVANT;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; ENZYME ACTIVITY; IMMUNIZATION; IMMUNOREGULATION; NONHUMAN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; B-LYMPHOCYTES; CHOLERA TOXIN; ENZYME ACTIVATION; GENE TARGETING; HUMANS; IMMUNITY, MUCOSAL; RECOMBINANT FUSION PROTEINS;

EID: 0031815672     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00750.x     Document Type: Article

References (47)

1. WHO. Global Program on Vaccine Research & Development: Report of the Technical Review Group Meeting, 9-10 June 1997 WHO, 1997.
2. McGhee JR, Mestecky J, Dertzbaugh MT et al. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 1992; 10: 75-88.
3. Lycke N. A molecular approach to the construction of an effective mucosal vaccine adjuvant. Studies based on cholera toxin ADP-ribosylation and cell targeting. In: Kagnoff MF, Kiyono H (eds) Essentials of Mucosal Immunology. Academic Press, 1996; 563-80.
4. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J (eds) Handbook of Mucosal Immunology. Academic Press, 1994; 391-402.
5. Röcken M, Racke M, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 1996; 17: 225-31.
6. Mowat A. Oral tolerance and regulation of immunity to dietary antigens. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JP, Bienenstock J (eds) Handbook of Mucosal Immunology. Academic Press, 1994; 185.
7. Weiner HL. Oral tolerance: Immunologic mechanisms and treatment of autoimmune diseases. In: Kagnoff MF, Kiyono H (eds) Essentials of Mucosal Immunology. Academic Press, 1996; 555-61.
8. Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-22.
9. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991; 59: 2978-86.
10. Grdic D, Hörnquist E, Kjerrulf M, Lycke N. Lack of local suppression in orally tolerant CD8 deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J. Immunol. 1998; 160: 754-62.
11. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 1984; 133: 2892-7.
12. Zhang RG, Scott DL, Westbrook ML et al. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 1995; 251: 563-73.
13. Pizza M, Domenighini M, Hol W et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 1994; 14: 51-60.
14. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992; 56: 622-47.
15. Merritt EA, Hol WG. AB5 toxins. Curr. Opin. Struct. Biol. 1995; 5: 165-71.
16. Takahashi I, Marinaro M, Kiyono H et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 1996; 173: 627-35.
17. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 1997; 65: 2821-8.
18. Sixma TK, Kalk KH, van Zanten BA et al. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 1993; 230: 890-918.
19. Dallas WS, Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature 1980; 288: 499-501.
20. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl Acad. Sci. USA 1996; 93: 226-30.
21. Lycke N. Analysis of the second messenger systems involved in the synergistic effect of cholera toxin and interleukin-4 on B cell isotype-switching. Adv. Exp. Med. Biol. 1995; 15-20.
22. Vajdy M, Kosco-Vilbois M, Kopf M, Köhler G, Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 1995; 181: 41-53.
23. Kjerrulf M, Grdic D, Ekman L et al. Interferon-γ deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance. Immunology 1997; 92: 60-8.
24. Hörnquist E, Grdic D, Mak T, Lycke N. CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effect of cholera toxin. Immunology 1996; 87: 220-9.
25. Ågren L, Ekman L, Löwenadler B, Lycke N. A genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 1997; 158: 3936-46.
26. + T cells to protein antigens in vivo. J. Immunol. 1995; 155: 3734-41.
27. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992; 22: 2277-81.
28. Liang X, Lamm ME, Nedrud JG. Cholera toxin as a mucosal adjuvant: Glutaraldehyde treatment dissociates adjuvanticity from toxicity. J. Immunol. 1989; 143: 484-90.
29. Levine MM, Kaper JB, Black RE, Clemens ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 1983; 47: 510-50.
30. Ljungberg UK, Jansson B, Niss U et al. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F (ab′)2: Separation of affinity from specificity. Mol. Immunol. 1993; 30: 1279-85.
31. Löwenadler B, Lycke N. Fusion proteins with heterologous T helper epitopes. Recombinant E. coli heat-stable enterotoxin proteins. Intern. Rev. Immunol. 1994; 11: 103-11.
32. Cassell DJ, Schwartz RH. A quantitative analysis of antigen-presenting cell function; activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing co-stimulation. J. Exp. Med. 1994; 180: 1829-40.
33. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen presenting cells for priming CD4+ T cells to protein antigens in vivo. J. Immunol. 1995; 155: 3734-41.
34. Stockinger B, Zal T, Zal A, Gray D. B cells solicit their own help from T cells. J. Exp. Med. 1996; 183: 891-9.
35. Cong Y, Weaver C, Elson C. The mucosal adjuvanticity of cholera toxin involves enhancement of co-stimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 1997; 159: 5301.
36. Francis ML, Okazaki I, Moss J et al. cAmp-independent effects of cholera toxin on B cell activation, Iii. Cholera toxin a subunit-mediated ADP-ribosylation acts synergistically with ionomycin or IL-4 to induce B cell proliferation. J. Immunol. 1995; 154: 4956-64.
37. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 1995; 63: 1617-23.
38. Douce G, Turcotte C, Cropley I et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl Acad. Sci. USA 1995; 92: 1644-8.
39. de Haan L, Verweij WR, Feil IK et al. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 1996; 64: 5413-16.
40. Yamamoto S, Kiyono H, Yamamoto M et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA 1997; 94; 5267-72.
41. Yamamoto S, Takeda Y, Yamamoto M et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrhea-genicity but retain adjuvanticity. J. Exp. Med. 1997; 185: 1203-10.
42. Burnette WN, Mar VL, Platler BW et al. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity. Infect. Immun. 1991; 59: 4266-70.
43. Grant CC, Messer RJ, Cieplak W Jr. Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect. Immun. 1994; 62: 4270-8.
44. Magagnoli C, Manetti R, Fontana MR et al. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin. Infect. Immun. 1996; 64: 5434-8.
45. Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 1993; 61: 314-20.
46. Hajishengallis G, Hollingshead SK, Koga T, Russell MW. Mucosal immunization with bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 1995; 154: 4322-32.
47. Hörnquist E, Goldschmidt TJ, Holmdahl R, Lycke N. Host defence against cholera toxin is strongly CD4+ T cell dependent. Infect. Immun. 1991; 59: 3630-8.